{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:59:42Z","timestamp":1787165982332,"version":"build-2736575974"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erenumab was approved in Europe for migraine prevention in patients with\u2009\u2265\u20094 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The Spanish Neurological Society started a prospective registry to evaluate real-world effectiveness and tolerability, and all Spanish headache experts were invited to participate. We present their first results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients fulfilled the ICHD-3 criteria for migraine and had\u2009\u2265\u20094 MMDs. Sociodemographic and clinical data were registered as well as MMDs, monthly headache days, MHDs, prior and concomitant preventive treatment, medication overuse headache (MOH), migraine evolution, adverse events, and patient-reported outcomes (PROs): headache impact test (HIT-6), migraine disability assessment questionnaire (MIDAS), and patient global improvement change (PGIC). A\u2009&gt;\u200950% reduction of MMDs after 12\u00a0weeks was considered as a response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 210 patients (female 86.7%, mean age 46.4\u00a0years old) from 22 Spanish hospitals from February 2019 to June 2020. Most patients (89.5%) suffered from chronic migraine with a mean evolution of 8.6\u00a0years. MOH was present in 70% of patients, and 17.1% had migraine with aura. Patients had failed a mean of 7.8 preventive treatments at baseline (botulinum toxin type A\u2014BoNT\/A\u2014had been used by 95.2% of patients). Most patients (67.6%) started with erenumab 70\u00a0mg. Sixty-one percent of patients were also simultaneously taking oral preventive drugs and 27.6% were getting simultaneous BoNT\/A. Responder rate was 37.1% and the mean reduction of MMDs and MHDs was -6.28 and -8.6, respectively. Changes in PROs were: MIDAS: -35 points, HIT-6: -11.6 points, PIGC: 4.7 points. Predictors of good response were prior HIT-6 score\u2009&lt;\u200980 points (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01),\u2009\u2264\u20095 prior preventive treatment failures (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026), absence of MOH (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039), and simultaneous BoNT\/A treatment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Twenty percent of patients had an adverse event, but only two of them were severe (0.9%), which led to treatment discontinuation. Mild constipation was the most frequent adverse event (8.1%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real-life, in a personalized managed access program, erenumab shows a good effectiveness profile and an excellent tolerability in migraine prevention in our cohort of refractory patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-021-01267-x","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T03:03:06Z","timestamp":1626490986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention"],"prefix":"10.1186","volume":"22","author":[{"given":"Robert","family":"Belv\u00eds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Irimia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gonz\u00e1lez-Oria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Viguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Oterino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"G\u00f3mez-Camello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Alberte-Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Oms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ezpeleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier D\u00edaz","family":"de Ter\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Moroll\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torres-Ferr\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Lamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"Leira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita S\u00e1nchez","family":"del R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,17]]},"reference":[{"key":"1267_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Lifting the Burden: The Global Campaign against Headache (2020) Migraine remains second among the world\u00b4s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137","journal-title":"J Headache Pain"},{"key":"1267_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343\u2013349","journal-title":"Neurology"},{"key":"1267_CR3","unstructured":"Santos S, Pozo-Rosich P (2020) Headache clinical practice manual. Spanish Society of Neurology. Madrid: Ed. Luzon 5 SA"},{"key":"1267_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2018) Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38:815\u2013832","journal-title":"Cephalalgia"},{"key":"1267_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1533-2500.2012.00530.x","volume":"12","author":"A Berger","year":"2012","unstructured":"Berger A, Bloudek LM, Varon SF, Oster G (2012) Adherence with migraine prophylaxis in clinical practice. Pain Pract 12:541\u2013549","journal-title":"Pain Pract"},{"key":"1267_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37:470\u2013485","journal-title":"Cephalalgia"},{"key":"1267_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1468-2982.2009.01909.x","volume":"30","author":"JE Lafata","year":"2010","unstructured":"Lafata JE, Tunceli O, Cerghet M, Sharma KP, Lipton RB (2010) The use of migraine preventive medications among patients with and without migraine headaches. Cephalalgia 30:97\u2013104","journal-title":"Cephalalgia"},{"key":"1267_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0333102416684344","volume":"38","author":"H Ashina","year":"2018","unstructured":"Ashina H, Schytz HW, Ashina M (2018) CGRP in human models of primary headaches. Cephalalgia 38:353\u2013360","journal-title":"Cephalalgia"},{"key":"1267_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410230214","volume":"23","author":"PJ Goadsby","year":"1988","unstructured":"Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23:193\u2013196","journal-title":"Ann Neurol"},{"key":"1267_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11916-017-0618-8","volume":"21","author":"N Riesco","year":"2017","unstructured":"Riesco N, Cernuda-Moroll\u00f3n E, Pascual J (2017) Neuropeptides as a marker for chronic headache. Curr Pain Headache Rep 21:18","journal-title":"Curr Pain Headache Rep"},{"key":"1267_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/head.12372","volume":"54","author":"E Cernuda-Moroll\u00f3n","year":"2014","unstructured":"Cernuda-Moroll\u00f3n E, Mart\u00ednez-Camblor P, Ram\u00f3n C, Larrosa D, Serrano-Pertierra E, Pascual J (2014) CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache 54:987\u2013995","journal-title":"Headache"},{"key":"1267_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0333102410368444","volume":"30","author":"JM Hansen","year":"2010","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30:1179\u20131186","journal-title":"Cephalalgia"},{"key":"1267_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100\u20131107","journal-title":"Lancet Neurol"},{"key":"1267_CR14","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13:885\u2013892","journal-title":"Lancet Neurol"},{"key":"1267_CR15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1081\u20131090","journal-title":"Lancet Neurol"},{"key":"1267_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1091\u20131100","journal-title":"Lancet Neurol"},{"key":"1267_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M et al (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:382\u2013390","journal-title":"Lancet Neurol"},{"key":"1267_CR18","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/0333102419858355","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J et al (2019) Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia 39:1075\u20131085","journal-title":"Cephalalgia"},{"key":"1267_CR19","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:2113\u20132122","journal-title":"N Engl J Med"},{"key":"1267_CR20","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2017","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2017) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 38:1442\u20131454","journal-title":"Cephalalgia"},{"key":"1267_CR21","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of Erenumab for episodic migraine. N Engl J Med 377:2123\u20132132","journal-title":"N Engl J Med"},{"key":"1267_CR22","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2017","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al (2017) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037","journal-title":"Cephalalgia"},{"key":"1267_CR23","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280\u20132287","journal-title":"Lancet"},{"key":"1267_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","volume":"75","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A et al (2018) Effect of different doses of Galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol 75:187\u2013193","journal-title":"JAMA Neurol"},{"key":"1267_CR25","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319:1999\u20132008","journal-title":"JAMA"},{"key":"1267_CR26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75:1080\u20131088","journal-title":"JAMA Neurol"},{"key":"1267_CR27","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/head.13421","volume":"58","author":"SD Silberstein","year":"2018","unstructured":"Silberstein SD, Kudrow D, Saper J, Janelidze M, Smith T, Dodick DW et al (2018) Eptinezumab results for the prevention of episodic migraine over one year in the PROMISE-1 (PRevention of migraine via intravenous Eptinezumab safety and efficacy-1) trial. Headache 58:1298","journal-title":"Headache"},{"key":"1267_CR28","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: The randomized, double-blind, placebo controlled REGAIN study. Neurology 91:e2211\u2013e2221","journal-title":"Neurology"},{"key":"1267_CR29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394:1030\u20131040","journal-title":"Lancet"},{"key":"1267_CR30","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z et al (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92:e2309\u2013e2320","journal-title":"Neurology"},{"key":"1267_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:241\u2013254","journal-title":"Cephalalgia"},{"key":"1267_CR32","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94:e1365\u2013e1377","journal-title":"Neurology"},{"key":"1267_CR33","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","volume":"394","author":"A Charles","year":"2019","unstructured":"Charles A, Pozo-Rosich P (2019) Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 394:1765\u20131774","journal-title":"Lancet"},{"key":"1267_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10194-017-0750-1","volume":"18","author":"M Hou","year":"2017","unstructured":"Hou M, Xing H, Cai Y, Li B, Wang X, Li P et al (2017) The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain 18:42","journal-title":"J Headache Pain"},{"key":"1267_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.clineuro.2017.01.009","volume":"154","author":"P Hong","year":"2017","unstructured":"Hong P, Wu X, Liu Y (2017) Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta-analysis. Clin Neurol Neurosurg 154:74\u201378","journal-title":"Clin Neurol Neurosurg"},{"key":"1267_CR36","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s10072-018-3547-3","volume":"39","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Liu Y, Zhao J, Han Q, Liu L, Shen X (2018) The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol Sci 39:2097\u20132106","journal-title":"Neurol Sci"},{"key":"1267_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","volume":"79","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M et al (2019) Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs 79:417\u2013431","journal-title":"Drugs"},{"key":"1267_CR38","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1177\/0333102419829007","volume":"39","author":"D Xu","year":"2019","unstructured":"Xu D, Chen D, Zhu LN, Tan G, Wang HJ, Zhang Y et al (2019) Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. Cephalalgia 39:1164\u20131179","journal-title":"Cephalalgia"},{"key":"1267_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","volume":"20","author":"H Deng","year":"2020","unstructured":"Deng H, Li GG, Nie H, Feng YY, Guo GY et al (2020) Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. BMC Neurol 20:57","journal-title":"BMC Neurol"},{"key":"1267_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society (2019) The American headache society position statement on integrating new migraine treatments into clinical practice. Headache 59:1\u201318","journal-title":"Headache"},{"key":"1267_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6","journal-title":"J Headache Pain"},{"key":"1267_CR42","unstructured":"Santos-Lasaosa S, Belv\u00eds R, Cuadrado ML, D\u00edaz-Insa S, Gago-Veiga A, Guerrero-Peral AL, Huerta M, Irimia P, L\u00e1inez JM, Latorre G, Leira R, Pascual J, Porta-Etessam J, S\u00e1nchez Del R\u00edo M, Viguera J, Pozo-Rosich P. (2019) Neurologia (Engl Ed). S0213-4853(19)30075-1"},{"key":"1267_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211","journal-title":"Cephalalgia"},{"key":"1267_CR44","doi-asserted-by":"crossref","unstructured":"epper SJ, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein SD, Winner P, Zhang F, Cheng S, Mikol DD. (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia. 40(6):543-553","DOI":"10.1177\/0333102420912726"},{"key":"1267_CR45","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ et al (2019) Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia 39:1798\u20131808","journal-title":"Cephalalgia"},{"key":"1267_CR46","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0333102419854082","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA et al (2019) Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 39:1455\u20131464","journal-title":"Cephalalgia"},{"key":"1267_CR47","unstructured":"Robbins L, Phenicie B (2018) Early data on the 1st migraine-inhibiting CGRP. In: Practical pain management"},{"key":"1267_CR48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10072-019-03839-x","volume":"40","author":"P Barbanti","year":"2019","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L (2019) Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci 40:177\u2013179","journal-title":"Neurol Sci"},{"key":"1267_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:32","journal-title":"J Headache Pain"},{"key":"1267_CR50","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ (2020) Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 60:2014\u20132025","journal-title":"Headache"},{"key":"1267_CR51","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40:1511\u20131522","journal-title":"Cephalalgia"},{"key":"1267_CR52","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21:84","journal-title":"J Headache Pain"},{"key":"1267_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61","journal-title":"J Headache Pain"},{"key":"1267_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21:69","journal-title":"J Headache Pain"},{"key":"1267_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61:363\u2013372","journal-title":"Headache"},{"key":"1267_CR56","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10072-020-04658-1","volume":"41","author":"U Pensato","year":"2020","unstructured":"Pensato U, Favoni V, Pascazio A, Benini M, Asioli GM, Merli E et al (2020) Erenumab efficacy in highly resistant chronic migraine: a real-life study. Neurol Sci 41:457\u2013459","journal-title":"Neurol Sci"},{"key":"1267_CR57","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10072-020-04665-2","volume":"41","author":"C Disco","year":"2020","unstructured":"Disco C, Billo G, De Boni A, De Luca C, Perini F (2020) Efficacy of erenumab 70 mg in chronic migraine: Vicenza experience. Neurol Sci 41:479\u2013480","journal-title":"Neurol Sci"},{"key":"1267_CR58","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10072-020-04670-5","volume":"41","author":"F Schiano di Cola","year":"2020","unstructured":"Schiano di Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U et al (2020) Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study. Neurol Sci 41:489\u2013490","journal-title":"Neurol Sci"},{"key":"1267_CR59","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10072-020-04667-0","volume":"41","author":"E Matteo","year":"2020","unstructured":"Matteo E, Favoni V, Pascazio A, Pensato U, Benini M, Asioli GM et al (2020) Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center. Neurol Sci 41:483\u2013484","journal-title":"Neurol Sci"},{"key":"1267_CR60","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in chronic migraine: an Australian experience. Headache 60:2555\u20132562","journal-title":"Headache"},{"key":"1267_CR61","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10072-020-04677-y","volume":"41","author":"A Ranieri","year":"2020","unstructured":"Ranieri A, Alfieri G, Napolitano M, Servillo G, Candelaresi P, Di Iorio W et al (2020) One year experience with erenumab: real-life data in 30 consecutive patients. Neurol Sci 41:505\u2013506","journal-title":"Neurol Sci"},{"key":"1267_CR62","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10072-020-04752-4","volume":"41","author":"ED Valle","year":"2020","unstructured":"Valle ED, Di Falco M, Mancioli A, Corbetta S, La Spina I et al (2020) Efficacy and safety of erenumab in the real-life setting of S. Antonio Abate Hospital\u2019s Headache Center (Gallarate). Neurol Sci 41:465","journal-title":"Neurol Sci"},{"key":"1267_CR63","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"11","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A et al (2020) Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 11:417","journal-title":"Front Neurol"},{"key":"1267_CR64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-019-1054-4","volume":"20","author":"R Ornello","year":"2019","unstructured":"Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F et al (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain 20:99","journal-title":"J Headache Pain"},{"key":"1267_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","volume":"35","author":"M Armanious","year":"2021","unstructured":"Armanious M, Khalil N, Lu Y, Jimenez-Sanders R (2021) Erenumab and onabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother 35:1\u20136","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"1267_CR66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","volume":"22","author":"J Talbot","year":"2021","unstructured":"Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S (2021) Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes. J Headache Pain 22:5","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01267-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-021-01267-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01267-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:08:11Z","timestamp":1699229291000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-021-01267-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1267"],"URL":"https:\/\/doi.org\/10.1186\/s10194-021-01267-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-268641\/v1","asserted-by":"object"}]},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,17]]},"assertion":[{"value":"28 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MAB-MIG was classified as a <i>low-intervention clinical trial<\/i> by the Spanish Medicines Agency and Medical Devices and was approved by the Ethics Committee of Investigation with Medicines of the Health Area of Valladolid, Spain (PI 20\u20131790).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Authors consent the publication of the paper MAB-MIG: REGISTRY OF THE SPANISH NEUROLOGICAL SOCIETY OF ERENUMAB FOR MIGRAINE PREVENTION. THREE-MONTHS RESULTS in The Journal of Headache and Pain.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Within the prior 24\u00a0months, RB, PI, PP-R, CG-O, and MSDR have received honoraria as consultant and\/or speaker for Eli-Lilly, Novartis, Teva, and Allergan\/Abbvie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}